AstraZeneca's Boston BioHub announces on-boarding of Blue Oak Pharmaceuticals
AstraZeneca’s Boston BioHub is excited to announce the arrival of Blue Oak Pharmaceuticals, its first company to on-board as a life science incubator resident.
Moving to the Boston BioHub in January 2018, Blue Oak Pharmaceuticals is a biopharmaceutical company committed to finding the next generation of drugs for brain disorders. They combine validated in vivo systems neurobiology measures with an innovative chemistry platform (ADEPtTM) to develop new medicines that target dysfunctional brain circuits.
“We are pleased to be part of the BioHub community and AstraZeneca’s forward-looking approach to collaboration between start-ups and established pharma. One of the key challenges that all start-ups face is to find an environment where new approaches can be ‘pressure tested’. The depth of scientific expertise that is available here will certainly help Blue Oak to reach our goals.” said Kerry Spear, Blue Oak’s Chief Science Officer.